ACTRN12607000361404招募中2 期
Children Under the Age of 16 Will Be Tested With A Therapeutic Intervention, Pulsed Electromagnetic Field Therapy and Compared To Treatment with Pharmaceutical Drugs For Treatment of Asthma as Measured By Symptoms, Amount of Medication Required and Peak Flows Over a 12 week Period. They will be followed up over a 52 week period for long term changes.
Biological Control Systems Pty Ltd.0 个研究点目标入组 20 人开始时间: 2007年7月6日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 3 Months 至 16 Years（—）
- 性别
- All
入选标准
- •Children, infants and babies. Trial participants must have been diagnosed with asthma and have been treated for at least 3 months prior to enrolment.
排除标准
- •Do not satisfy the inclusion criteria.
研究者
相似试验
进行中（未招募）
不适用
INTERGROUP TRIAL FOR CHILDREN OR ADOLESCENTS WITH B-CELL NHL OR B-AL: EVALUATION OF RITUXIMAB EFFICACY AND SAFETY IN HIGH RISK PATIENTSntreated children or adolescents with PMLBLMedDRA version: 14.1Level: PTClassification code 10036710Term: Primary mediastinal large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019224-31-ITA.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA40
已完成
3 期
INTERGROUP TRIAL FOR CHILDREN OR ADOLESCENTS WITH B-CELL NHL OR B-AL: EVALUATION OF RITUXIMAB EFFICACY AND SAFETY IN HIGH RISK PATIENTSNon-Hodgkin Lymphoma10025320NL-OMON55528Institut Gustave Roussy18
尚未招募
不适用
Study of Ultrasound in Forearm Fractures versus Investigation with X-rayForearm injuries from trauma in children- looking for potential fractures.Injuries and Accidents - FracturesACTRN12611001085965Prof. G Geelhoed400
进行中（未招募）
1 期
INTERGROUP TRIAL FOR CHILDREN OR ADOLESCENTSWITH B-CELL NHL OR B-AL: EVALUATIONOF RITUXIMAB EFFICACY AND SAFETY IN HIGH RISK PATIENTSEUCTR2010-019224-31-NLInstitut Gustave Roussy529
进行中（未招募）
不适用
INTERGROUP TRIAL FOR CHILDREN OR ADOLESCENTSWITH B-CELL NHL OR B-AL: EVALUATIONOF RITUXIMAB EFFICACY AND SAFETY IN HIGH RISK PATIENTSEUCTR2010-019224-31-ESInstitut Gustave Roussy640